Company / Current Liabilities per Share
VYNE Therapeutics Inc. Current Liabilities per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$1.00
FY2025
5-year range
$1.00 / $2.33
FY2021-FY2025
Trend
-4.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities per Share has declined for 3 consecutive years, from $2.35 in FY2020 to $1.00 in FY2025.
Based on SEC 10-K filings.
1.00 in FY2025 with a 5-year CAGR of -15.7%.
Improved from $2.33 to $1.00 over the past 2 years.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -15.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, current liabilities per share decreased 4.9% year-over-year.
- Peak current liabilities per share was recorded in FY2020.
- Lowest current liabilities per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.00 | -4.9% |
| FY2024 | $1.05 | -55.0% |
| FY2023 | $2.33 | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $2.35 | +412.6% |
| FY2019 | $0.46 | -74.5% |
| FY2018 | $1.80 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026